Valneva SE Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/22/2026)
| Balance Sheet | Total Assets | 398,836,000.00 | ROE | 26.62 % |
| Balance Sheet | Total Equity | 106,168,000.00 | ROA | -28.88 % |
| Cashflow | Capital Expenditures | -4,481,000.00 | P/FCF | -7.67 |
| Cashflow | Free Cash Flow | -57,375,000.00 | – | – |
| Cashflow | Operating Cash Flow | -52,894,000.00 | P/CF | -8.31 |
| Income | Earnings per Share (diluted) | -0.66 | Div. Yield | – |
| Income | Net Income | -115,192,000.00 | P/E | -3.84 |
| Income | Shares Outstanding | 173,415,000.00 | P/B | 4.14 |
| Income | Total Revenue | 174,658,000.00 | P/S | 2.52 |
Ratios calculated on: 10/14/2026
Company Description
Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.valneva.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more